Drug Profile
Research programme: small molecule therapeutics - Eli Lilly and Company/Locus
Latest Information Update: 24 Mar 2009
Price :
$50
*
At a glance
- Originator Eli Lilly and Company; Locus Pharmaceuticals
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 27 Feb 2006 Preclinical trials in Undefined in USA (unspecified route)